report.It contains the annual financial statements,consolidated financial statements and non-financial perance indicators.It covers all regions and divisions of the Roche Group from 1January to 31 December 2022.The financial reporting scope is defined and outlined in our Finance Report,and there have...
As a pioneer in healthcare, we have been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally.
efficacy and safety of atezolizumab subcutaneous (SC) vs intravenous (IV) in previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC). Presented at ESMO IO; 7-9 Dec 2022. Abstract #61MO.
The Australian Examination Report, dated Jan. 22, 2016, in the corresponding Australian application No. 2010335277. The English translation of the Japanese Office Action, dated Jan. 20, 2015, in the corresponding Japanese Application No. 2012-545252. The European Communication, dated Mar. 31,...
By their nature, these statements are subject to numerous risks and uncertainties, including those risks and uncertainties set forth in our most recent Annual Report on Form 10-K for the year ended December 31, 2022, filed with the U.S. Securities and Exchange Commission on March...
Roche Group sales: CHF 63.3 billion +2% Pharmaceuticals Division sales: CHF 45.6 billion +3% Diagnostics Division sales: CHF 17.7 billion +3% Core investments in research and development: CHF 14.1 billion +3% Core operating profit: CHF 22.2 billion ...